Proteomic analysis of plasma samples from patients with acute myocardial infarction identifies haptoglobin as a potential prognostic biomarker

Journal of Proteomics

Volumn 75, Issue 1, 2011, Pages 229-236

  Haas, Benjamin ^a   Serchi, Tommaso ^b   Wagner, Daniel R ^c   Gilson, Georges ^c   Planchon, Sebastien ^b   Renaut, Jenny ^b   Hoffmann, Lucien ^b   Bohn, Torsten ^b   Devaux, Yvan ^a  

^a LUXEMBOURG INSTITUTE OF HEALTH   (Luxembourg)

^b LUXEMBOURG INSTITUTE OF SCIENCE AND TECHNOLOGY   (Luxembourg)

^c Centre Hospitalier   (Luxembourg)

Author keywords

2 D DiGE; Biomarkers; Haptoglobin; Heart failure; Myocardial infarction; Plasma proteins

Indexed keywords

ALBUMIN; C REACTIVE PROTEIN; CREATINE KINASE; GELATINASE B; HAPTOGLOBIN; IMMUNOGLOBULIN G; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TROPONIN T; BIOLOGICAL MARKER; ISOPROTEIN;

ADULT; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CREATINE KINASE BLOOD LEVEL; DISEASE SEVERITY; ELECTROCARDIOGRAM; EXTRACELLULAR MATRIX; FEMALE; FOLLOW UP; GENOTYPE; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FUNCTION; HUMAN; MALE; PRINCIPAL COMPONENT ANALYSIS; PRIORITY JOURNAL; PROGNOSIS; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEOMICS; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; ACUTE DISEASE; BLOOD; GENETICS; HEART INFARCTION; METABOLISM; METHODOLOGY; MIDDLE AGED; PATHOLOGY;

ACUTE DISEASE; BIOLOGICAL MARKERS; HAPTOGLOBINS; HEART FAILURE; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PROGNOSIS; PROTEIN ISOFORMS; PROTEOMICS;

EID: 82655161290     PISSN: 18743919     EISSN: 18767737     Source Type: Journal    
DOI: 10.1016/j.jprot.2011.06.028     Document Type: Article

References (32)

1. Heidenreich P.A., Trogdon J.G., Khavjou O.A., Butler J., Dracup K., Ezekowitz M.D., et al. Circulation 2011, 122:933-944.
2. Torabi A., Cleland J.G., Khan N.K., Loh P.H., Clark A.L., Alamgir F., et al. The timing of development and subsequent clinical course of heart failure after a myocardial infarction. Eur Heart J 2008, 29:859-870.
3. Ezekowitz J.A., Kaul P., Bakal J.A., Armstrong P.W., Welsh R.C., McAlister F.A. Declining in-hospital mortality and increasing heart failure incidence in elderly patients with first myocardial infarction. J Am Coll Cardiol 2009, 53:13-20.
4. Spinale F.G. Myocardial matrix remodeling and the matrix metalloproteinases: influence on cardiac form and function. Physiol Rev 2007, 87:1285-1342.
5. Yan A.T., Yan R.T., Spinale F.G., Afzal R., Gunasinghe H.R., Arnold M., et al. Plasma matrix metalloproteinase-9 level is correlated with left ventricular volumes and ejection fraction in patients with heart failure. J Card Fail 2006, 12:514-519.
6. Wagner D.R., Delagardelle C., Ernens I., Rouy D., Vaillant M., Beissel J. Matrix metalloproteinase-9 is a marker of heart failure after acute myocardial infarction. J Card Fail 2006, 12:66-72.
7. Kelly D., Cockerill G., Ng L.L., Thompson M., Khan S., Samani N.J., et al. Plasma matrix metalloproteinase-9 and left ventricular remodelling after acute myocardial infarction in man: a prospective cohort study. Eur Heart J 2007, 28:711-718.
8. Azuaje F., Devaux Y., Vausort M., Yvorra C., Wagner D.R. Transcriptional networks characterize ventricular dysfunction after myocardial infarction: a proof-of-concept investigation. J Biomed Inform 2010, 43:812-819.
9. Azuaje F., Devaux Y., Wagner D.R. Coordinated modular functionality and prognostic potential of a heart failure biomarker-driven interaction network. BMC Syst Biol 2010, 4:60.
10. Azuaje F., Devaux Y., Wagner D.R. Integrative pathway-centric modeling of ventricular dysfunction after myocardial infarction. PLoS One 2010, 5:e9661.
11. Devaux Y., Azuaje F., Vausort M., Yvorra C., Wagner D.R. Integrated protein network and microarray analysis to identify potential biomarkers after myocardial infarction. Funct Integr Genomics 2010, 10:329-337.
12. Lasserre J.P., Fack F., Revets D., Planchon S., Renaut J., Hoffmann L., et al. Effects of the endocrine disruptors atrazine and PCB 153 on the protein expression of MCF-7 human cells. J Proteome Res 2009, 8:5485-5496.
13. Renaut J., Hausman J.F., Bassett C., Artlip T., Cauchie H.M., Witters E., et al. Quantitative proteomic analysis of short photoperiod and low-temperature responses in bark tissues of peach [Prunus persica L. Batsch]. Tree Genet Genomes 2008, 4:589-600.
14. Tseng C.F., Huang H.Y., Yang Y.T., Mao S.J. Purification of human haptoglobin 1-1, 2-1, and 2-2 using monoclonal antibody affinity chromatography. Protein Expr Purif 2004, 33:265-273.
15. Van Eyk J.E. Overview: the maturing of proteomics in cardiovascular research. Circ Res 2011, 108:490-498.
16. Edwards A.V., White M.Y., Cordwell S.J. The role of proteomics in clinical cardiovascular biomarker discovery. Mol Cell Proteomics 2008, 7:1824-1837.
17. Lathrop J.T., Anderson N.L., Anderson N.G., Hammond D.J. Therapeutic potential of the plasma proteome. Curr Opin Mol Ther 2003, 5:250-257.
18. Zhang R., Barker L., Pinchev D., Marshall J., Rasamoelisolo M., Smith C., et al. Mining biomarkers in human sera using proteomic tools. Proteomics 2004, 4:244-256.
19. Banfi C., Brioschi M., Barcella S., Veglia F., Biglioli P., Tremoli E., et al. Oxidized proteins in plasma of patients with heart failure: role in endothelial damage. Eur J Heart Fail 2008, 10:244-251.
20. Smithies O., Walker N.F. Genetic control of some serum proteins in normal humans. Nature 1955, 176:1265-1266.
21. Quaye I.K. Haptoglobin, inflammation and disease. Trans R Soc Trop Med Hyg 2008, 102:735-742.
22. Koch W., Latz W., Eichinger M., Roguin A., Levy A.P., Schomig A., et al. Genotyping of the common haptoglobin Hp 1/2 polymorphism based on PCR. Clin Chem 2002, 48:1377-1382.
23. Delanghe J., Langlois M., Duprez D., De Buyzere M., Clement D. Haptoglobin polymorphism and peripheral arterial occlusive disease. Atherosclerosis 1999, 145:287-292.
24. Quaye I.K., Ababio G., Amoah A.G. Haptoglobin 2-2 phenotype is a risk factor for type 2 diabetes in Ghana. J Atheroscler Thromb 2006, 13:90-94.
25. Costacou T., Ferrell R.E., Orchard T.J. Haptoglobin genotype: a determinant of cardiovascular complication risk in type 1 diabetes. Diabetes 2008, 57:1702-1706.
26. Levy A.P. Genetics of diabetic cardiovascular disease: identification of a major susceptibility gene. Acta Diabetol 2003, 40(Suppl. 2):S330-S333.
27. Asaf R., Blum S., Roguin A., Kalet-Litman S., Kheir J., Frisch A., et al. Haptoglobin genotype is a determinant of survival and cardiac remodeling after myocardial infarction in diabetic mice. Cardiovasc Diabetol 2009, 8:29.
28. Holme I., Aastveit A.H., Hammar N., Jungner I., Walldius G. Haptoglobin and risk of myocardial infarction, stroke, and congestive heart failure in 342,125 men and women in the Apolipoprotein MOrtality RISk study [AMORIS]. Ann Med 2009, 41:522-532.
29. Alayash A.I. Oxygen therapeutics: can we tame haemoglobin?. Nat Rev 2004, 3:152-159.
30. Alayash A.I. Redox biology of blood. Antioxid Redox Signal 2004, 6:941-943.
31. Kristiansen M., Graversen J.H., Jacobsen C., Sonne O., Hoffman H.J., Law S.K., et al. Identification of the haemoglobin scavenger receptor. Nature 2001, 409:198-201.
32. de Kleijn D.P.V., Smeets M.B., Kemmeren P.P.W., Lim S.K., van Middelaar B.J., Velema E., et al. Acute-phase protein haptoglobin is a cell migration factor involved in arterial restructuring. FASEB J 2002, 16:1123-1125.